NICE Surgical Awarded U.S. Patent for Purse-String Stapler

Rhea-AI Summary

NICE Surgical Solutions, a clinical-stage medtech company, has been granted U.S. Patent No. 12,653,527 B2 for its purse-string stapler for colorectal surgery. The device enables intracorporeal purse-string suturing, stapling, and resection, targeting full intracorporeal anastomosis.

The patented technology is designed to complete colorectal procedures minimally invasively, without an abdominal incision, which may improve efficiency and reduce surgical site infections. NICE Surgical is a portfolio company of Trendlines (TRNGF). Human clinical studies are planned by Q4 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Grant of U.S. Patent No. 12,653,527 B2 for purse-string stapler
• Technology designed to enable minimally invasive colorectal surgery without abdominal incision
• Human clinical studies targeted to begin by Q4 2026

Negative

• None.

What This Means

This announcement highlights a newly granted U.S. patent and planned human studies by Q4 2026, reinf...

Analysis

This announcement highlights a newly granted U.S. patent and planned human studies by Q4 2026, reinforcing Trendlines’ medtech portfolio. Key risks remain clinical execution and adoption; progress into and through human trials is the main watchpoint.

Key Figures

Patent number: U.S. Patent No. 12,653,527 B2 Human clinical studies timing: Q4 2026 Price change (pre-news, 24h): -43.18% +5 more

8 metrics

Patent number U.S. Patent No. 12,653,527 B2 Purse-string stapler intellectual property grant

Human clinical studies timing Q4 2026 Planned start of NICE Surgical human clinical studies

Price change (pre-news, 24h) -43.18% Move in TRNGF prior to this patent announcement

Volume today 320,000 shares Trading activity before news vs 20-day average

20-day avg volume 16,147 shares Liquidity baseline for TRNGF

Relative volume 19.82x Today’s volume vs 20-day average before news

52-week high $0.0606 TRNGF trading range reference

52-week low $0.03 TRNGF trading range reference

Regulatory & Risk Context

Short Interest: 0.05%

Short Interest

0.05% of float

0% 15% 30%+

low as of 2025-03-31 Days to cover: 999.99

Reported short positioning appears relatively low, suggesting limited short-squeeze risk and a reduced likelihood that short-covering alone would drive extreme volatility.

Key Terms

intracorporeal anastomosis, purse-string suture, colorectal surgery, surgical site infections, +1 more

5 terms

intracorporeal anastomosis medical

"pioneering full intracorporeal anastomosis surgical instruments has been officially granted"

A surgical technique that reconnects two internal hollow organs — most often segments of intestine — entirely inside the body during minimally invasive procedures, rather than bringing the ends out through an incision. Think of it as joining two garden hoses inside a closed box instead of disconnecting them to work on the ends; it can reduce wound size and speed recovery. For investors, this matters because the approach can change procedure time, complication rates, device and robotic-tool demand, hospital costs, and payer reimbursement, all of which affect market adoption and revenue potential.

purse-string suture medical

"covers the efficient application of a purse-string suture around the tissue"

A purse-string suture is a circular stitch placed around the edge of an opening in tissue that can be tightened like a drawstring to close or secure that opening. Investors should care because this simple surgical technique can affect procedure time, complication rates and how well medical devices or therapies perform in trials; better, reliable closure often improves clinical outcomes, regulatory prospects and market acceptance.

colorectal surgery medical

"adjacent to the open lumen during the colorectal surgery. The suture enables"

Colorectal surgery is an operation on the colon, rectum and anus to treat conditions such as cancer, blockages, severe inflammation or injury. It matters to investors because the number and type of these procedures influence revenue and profit for hospitals, device makers, drug companies and diagnostic firms; regulatory approvals, surgical outcomes and how insurers pay for care can change market demand — like plumbing repairs driving business for toolmakers and contractors.

surgical site infections medical

"potentially increases the efficiency in surgery and reduces surgical site infections, usually associated"

Surgical site infections are infections that occur where a surgical cut was made, caused by bacteria or other germs entering the wound during or after an operation. They matter to investors because higher infection rates can increase hospital costs, lead to regulatory action, product recalls, lawsuits, and damaged reputations—similar to how a manufacturing defect forces costly recalls and repairs—so they affect revenue, margins, and risk for companies in healthcare and medical products.

clinical-stage medical

"NICE Surgical Solutions Pte Ltd ("NICE Surgical"), a clinical-stage medical device company pioneering"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enables intracorporeal purse-sting suturing, stapling, and resection in a single firing

SINGAPORE, July 1, 2026 /PRNewswire/ -- NICE Surgical Solutions Pte Ltd ("NICE Surgical"), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments has been officially granted the U.S. Patent No. 12,653,527 B2, for its purse-string stapler. 

This newly granted patent covers the efficient application of a purse-string suture around the tissue adjacent to the open lumen during the colorectal surgery. The suture enables the effective closure of the colon providing a full intracorporeal anastomosis at the completion of the surgery. The award of the patent validates NICE Surgical's use of advanced innovative medical solutions to improve surgical outcomes and the quality of life of patients.

The patented technology enables colorectal surgery to be completed minimally invasively, without an incision to the abdomen, as currently practiced. The use of NICE Surgical's device potentially increases the efficiency in surgery and reduces surgical site infections, usually associated with surgical incisions. 

NICE Surgical is a portfolio company of Trendlines Medical Singapore Pte Ltd ("Trendlines Medical Singapore"), a subsidiary of The Trendlines Group Ltd (SGX: 42T) (OTCQX: TRNLY), ("Trendlines"), an investment company focused on medtech and agrifood innovation. 

Haim Brosh, CEO of Trendlines said, "This patent is a testament to the dedication and ingenuity of the research and development team at NICE Surgical. With NICE Surgical's development progression, including human clinical studies by Q4 2026, this milestone further strengthens our validated technology."

"Medical innovation transforms scientific discovery into better patient outcomes. I am excited that the grant of this patent acknowledges the novelty, ingenuity and potential societal value of our medical innovation," commented co-founder and inventor, Eric Haas, MD, Chief of Colorectal Surgery Houston Methodist Hospital.

About The Trendlines Group Ltd.

The Trendlines Group (SGX: 42T) (OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

About NICE Surgical Solutions Pte Ltd

NICE Surgical is developing a stapling device that serves to divide the bowel at the proximal and distal level of resection as well as place a purse-string suture to prepare the bowel for the Intra Corporeal Anastomosis (ICA). The stapling device accomplishes two critical tasks by simultaneously stapling closed the specimen while applying a purse-string suture to the portion of the bowel to be used for an end-to-end circular stapled anastomosis.

Media contact:
Eric Loh
CEO Trendlines Medical Singapore
eric@trendlines.com

Photo: https://mma.prnewswire.com/media/3002888/NICE_Surgical_device.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nice-surgical-awarded-us-patent-for-purse-string-stapler-302815619.html

SOURCE NICE Surgical Solutions Pte Ltd

FAQ

What U.S. patent was granted to NICE Surgical and how could it affect Trendlines (TRNGF)?

NICE Surgical received U.S. Patent No. 12,653,527 B2 for its purse-string stapler for colorectal surgery. According to the company, the device supports full intracorporeal anastomosis, potentially enhancing Trendlines (TRNGF) medtech portfolio differentiation and long-term innovation pipeline.

How does NICE Surgical's purse-string stapler improve colorectal surgery outcomes?

The purse-string stapler enables intracorporeal suturing, stapling, and resection in a single firing for colorectal surgery. According to NICE Surgical, it allows minimally invasive completion without abdominal incision, potentially increasing surgical efficiency and reducing surgical site infections linked to incisions.

When are human clinical studies planned for NICE Surgical's patented stapler technology?

Human clinical studies for NICE Surgical's purse-string stapler are planned by Q4 2026. According to Trendlines, this clinical progression is expected to further validate the patented technology and could be an important milestone for investment in Trendlines (TRNGF).

What makes NICE Surgical's intracorporeal purse-string stapler technology unique?

The stapler enables a purse-string suture around tissue adjacent to the open lumen in colorectal surgery. According to NICE Surgical, this supports full intracorporeal anastomosis and may improve minimally invasive surgery by avoiding abdominal incisions and potentially lowering infection risk.

How is NICE Surgical related to Trendlines (TRNGF) and why is this patent relevant to investors?

NICE Surgical is a portfolio company of Trendlines Medical Singapore, a subsidiary of Trendlines (TRNGF). According to Trendlines, the patent grant strengthens validation of NICE Surgical’s technology, which may enhance the value and innovation profile of Trendlines’ medtech investments.